Resumen
The development of drugs that successfully target Bruton tyrosine kinase (BTK) represents a major scientific and clinical advance for the treatment of chronic lymphocytic leukaemia (CLL). This article will begin by reviewing the scientific observations that underpinned the targeting of this kinase in CLL. It will then discuss the evolution of BTK inhibitors, from the initial studies with ibrutinib, to the development of more specific and noncovalently binding BTK inhibitors, focusing on how different agents can be sequenced in patients who are resistant or intolerant to one of these drugs. Finally, this article will also review the concept of BTK degraders and offer insights into the future direction of the field.